Akt mediates TIGAR induction in HeLa cells following PFKFB3 inhibition

FEBS Letters

Volumn , Issue , 2016, Pages 2915-2926

  Simon Molas, Helga ^a   Calvo Vidal, María Nieves ^b   Castaño, Esther ^a   Rodríguez García, Ana ^a   Navarro Sabaté, Àurea ^a   Bartrons, Ramon ^a   Manzano, Anna ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Akt; glycolysis; PFKFB3; TIGAR; tumour cell metabolism

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE FRUCTOSE 2,6 BISPHOSPHATASE 3; APOPTOSIS REGULATORY PROTEIN; GLYCOLYTIC ENZYME; HISTONE H2AX; PROTEIN KINASE B; PROTEIN P62; REACTIVE OXYGEN METABOLITE; TP53 INDUCED GLYCOLYSIS AND APOPTOSIS REGULATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HELA CELL LINE; LETTER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84985911006     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1002/1873-3468.12338     Document Type: Article

References (43)

1. Van Schaftingen E (1987) Fructose 2,6-bisphosphate. Adv Enzymol Relat Areas Mol Biol 59, 315–395.
2. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG and Hue L (2004) 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J 381, 561–579.
3. Colomer D, Vives-Corrons JL, Pujades A and Bartrons R (1987) Control of phosphofructokinase by fructose 2,6-bisphosphate in B-lymphocytes and B-chronic lymphocytic leukemia cells. Cancer Res 47, 1859–1862.
4. Hue L and Rousseau GG (1993) Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes. Adv Enzyme Regul 33, 97–110.
5. Riera L, Manzano A, Navarro-Sabate A, Perales JC and Bartrons R (2002) Insulin induces PFKFB3 gene expression in HT29 human colon adenocarcinoma cells. Biochim Biophys Acta 1589, 89–92.
6. Calvo MN, Bartrons R, Castano E, Perales JC, Navarro-Sabate A and Manzano A (2006) PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett 580, 3308–3314.
7. Okar DA, Manzano A, Navarro-Sabate A, Riera L, Bartrons R and Lange AJ (2001) PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci 26, 30–35.
8. Goren N, Manzano A, Riera L, Ambrosio S, Ventura F and Bartrons R (2000) 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase expression in rat brain during development. Brain Res Mol Brain Res 75, 138–142.
9. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW and Chesney J (2006) Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 25, 7225–7234.
10. Sakakibara R, Uemura M, Hirata T, Okamura N and Kato M (1997) Human placental fructose-6-phosphate,2-kinase/fructose-2,6-bisphosphatase: its isozymic form, expression and characterization. Biosci Biotechnol Biochem 61, 1949–1952.
11. Manzano A, Rosa JL, Ventura F, Perez JX, Nadal M, Estivill X, Ambrosio S, Gil J and Bartrons R (1998) Molecular cloning, expression, and chromosomal localization of a ubiquitously expressed human 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase gene (PFKFB3). Cytogenet Cell Genet 83, 214–217.
12. Navarro-Sabate A, Manzano A, Riera L, Rosa JL, Ventura F and Bartrons R (2001) The human ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene (PFKFB3): promoter characterization and genomic structure. Gene 264, 131–138.
13. Bartrons R and Caro J (2007) Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 39, 223–229.
14. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R and Bucala R (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62, 5881–5887.
15. Chesney J (2006) 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care 9, 535–539.
16. Novellasdemunt L, Navarro-Sabate A, Manzano A, Rodríguez-García A and Bartrons R (2013) PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3). Atlas Genet Cytogenet Oncol Haematol 17, 609–622.
17. Obach M, Navarro-Sabate A, Caro J, Kong X, Duran J, Gomez M, Perales JC, Ventura F, Rosa JL and Bartrons R (2004) 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. J Biol Chem 279, 53562–53570.
18. Minchenko OH, Ochiai A, Opentanova IL, Ogura T, Minchenko DO, Caro J, Komisarenko SV and Esumi H (2005) Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie 87, 1005–1010.
19. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquiere B, Cauwenberghs S, Eelen G et al. (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154, 651–663.
20. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J et al. (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 7, 110–120.
21. Domenech E, Maestre C, Esteban-Martinez L, Partida D, Pascual R, Fernandez-Miranda G, Seco E, Campos-Olivas R, Perez M, Megias D et al. (2015) AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol 17, 1304–1316.
22. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E and Vousden KH (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120.
23. Gerin I, Noel G, Bolsee J, Haumont O, Van Schaftingen E and Bommer GT (2014) Identification of TP53-induced glycolysis and apoptosis regulator (TIGAR) as the phosphoglycolate-independent 2,3-bisphosphoglycerate phosphatase. Biochem J 458, 439–448.
24. Lee P, Vousden KH and Cheung EC (2014) TIGAR, TIGAR, burning bright. Cancer Metab 2, 1.
25. Won KY, Lim SJ, Kim GY, Kim YW, Han SA, Song JY and Lee DK (2012) Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer. Hum Pathol 43, 221–228.
26. Wanka C, Steinbach JP and Rieger J (2012) Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem 287, 33436–33446.
27. Cheung EC, Athineos D, Lee P, Ridgway RA, Lambie W, Nixon C, Strathdee D, Blyth K, Sansom OJ and Vousden KH (2013) TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell 25, 463–477.
28. Simon H, Rodríguez-García A, Navarro-Sabate A, Fontova P, Bartrons R and Manzano A (2014) C12orf5 (chromosome 12 open reading frame 5). Atlas Genet Cytogenet Oncol Haematol 18, 500–510.
29. Al-Khayal K, Abdulla M, Al-Obeed O, Al Kattan W, Zubaidi A, Vaali-Mohammed MA, Alsheikh A and Ahmad R (2016) Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients. Oncol Rep 35, 1281–1286.
30. Pena-Rico MA, Calvo-Vidal MN, Villalonga-Planells R, Martinez-Soler F, Gimenez-Bonafe P, Navarro-Sabate A, Tortosa A, Bartrons R and Manzano A (2011) TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells. Radiother Oncol 101, 132–139.
31. Van Schaftingen E, Lederer B, Bartrons R and Hers HG (1981) A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate. Eur J Biochem 129, 191–195.
32. Klarer AC, O'Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, Clem B, Chesney J and Telang S (2014) Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab 2, 2.
33. Liu Y, Song XD, Liu W, Zhang TY and Zuo J (2003) Glucose deprivation induces mitochondrial dysfunction and oxidative stress in PC12 cell line. J Cell Mol Med 7, 49–56.
34. Duran J, Obach M, Navarro-Sabate A, Manzano A, Gomez M, Rosa JL, Ventura F, Perales JC and Bartrons R (2009) Pfkfb3 is transcriptionally upregulated in diabetic mouse liver through proliferative signals. FEBS J 276, 4555–4568.
35. Trefely S, Khoo PS, Krycer JR, Chaudhuri R, Fazakerley DJ, Parker BL, Sultani G, Lee J, Stephan JP, Torres E et al. (2015) Kinome screen identifies PFKFB3 and glucose metabolism as important regulators of the insulin/insulin-like growth factor (IGF)-1 signaling pathway. J Biol Chem 290, 25834–25846.
36. Dong-Yun S, Yu-Ru D, Shan-Lin L, Ya-Dong Z and Lian W (2003) Redox stress regulates cell proliferation and apoptosis of human hepatoma through Akt protein phosphorylation. FEBS Lett 542, 60–64.
37. Gao M, Liang J, Lu Y, Guo H, German P, Bai S, Jonasch E, Yang X, Mills GB and Ding Z (2014) Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene 33, 745–755.
38. Warburg O (1956) On the origin of cancer cells. Science 123, 309–314.
39. Bensaad K, Cheung EC and Vousden KH (2009) Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J 28, 3015–3026.
40. Yu HP, Xie JM, Li B, Sun YH, Gao QG, Ding ZH, Wu HR and Qin ZH (2015) TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway. Sci Rep 5, 9853.
41. Kodiha M, Banski P and Stochaj U (2009) Interplay between MEK and PI3 kinase signaling regulates the subcellular localization of protein kinases ERK1/2 and Akt upon oxidative stress. FEBS Lett 583, 1987–1993.
42. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, Anastasiou D, Ito K, Sasaki AT, Rameh L et al. (2012) Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49–62.
43. Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, Matsumoto S, Sugiyama E, Ochiai A, Abe R et al. (2015) Signaling through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. J Biol Chem 290, 17495–17504.